Gefitinib. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy2

Cell Line, Tumor Tumor Cells, Cultured

Organisms4

Mice, Nude Mice, Inbred BALB C Mice, SCID Rats, Nude

Diseases49

Lung Neoplasms Carcinoma, Non-Small-Cell Lung Adenocarcinoma Exanthema Meningeal Carcinomatosis Head and Neck Neoplasms Carcinoma, Squamous Cell Lung Diseases, Interstitial Disease Progression Adenocarcinoma, Bronchiolo-Alveolar Brain Neoplasms Breast Neoplasms Neoplasm Recurrence, Local Neoplasms Brain Stem Neoplasms Carcinoma, Adenosquamous Diarrhea Meningeal Neoplasms Neoplasm Metastasis Glioma Neoplasm Invasiveness Glioblastoma Urologic Neoplasms Skin Diseases Carcinoma, Large Cell Urinary Bladder Neoplasms Neoplasms, Hormone-Dependent Colorectal Neoplasms Carcinoma, Bronchogenic Drug Eruptions Central Nervous System Neoplasms Bone Neoplasms Hematuria Acne Vulgaris Pleural Effusion, Malignant Vulvar Neoplasms Stomatitis Disease Models, Animal Carcinoma Pulmonary Fibrosis Prostatic Neoplasms Rhabdoid Tumor Radiation Pneumonitis Pancreatic Neoplasms Carcinoma, Neuroendocrine Esophageal Neoplasms Meningitis Mesothelioma Neoplasms, Unknown Primary

Chemicals and Drugs91

Quinazolines Receptor, Epidermal Growth Factor Antineoplastic Agents Protein Kinase Inhibitors Receptor, erbB-3 Proto-Oncogene Proteins c-akt Receptor, erbB-2 Epidermal Growth Factor Antibodies, Monoclonal, Humanized Taxoids Topotecan Quinazolinones Proto-Oncogene Proteins Protein-Tyrosine Kinases Proto-Oncogene Proteins c-met Paclitaxel Cisplatin ras Proteins Tumor Markers, Biological Camptothecin ATP-Binding Cassette Transporters Extracellular Signal-Regulated MAP Kinases Carboplatin Antibodies, Monoclonal Mitogen-Activated Protein Kinase 3 Biomarkers, Pharmacological Transforming Growth Factor alpha Deoxycytidine PTEN Phosphohydrolase Protein-Serine-Threonine Kinases Receptor, IGF Type 1 Keratin-19 DNA, Neoplasm Phosphatidylinositol 3-Kinases Neoplasm Proteins Guanine Ki-67 Antigen Vanilmandelic Acid Luteolin Platinum Compounds Glutamates Pyrazoles Enzyme Inhibitors Cyclin-Dependent Kinase Inhibitor p27 Nitriles Mitogen-Activated Protein Kinase 1 Matrix Metalloproteinase 11 Organoplatinum Compounds Heterocyclic Compounds, 3-Ring Fluorouracil Cadaverine Sulfonamides Hepatocyte Growth Factor RNA, Small Interfering Triazoles Hydroxychloroquine Mitogen-Activated Protein Kinase Kinases Mitoxantrone Midazolam Estramustine Mitogen-Activated Protein Kinases Oncogene Protein v-akt Ubiquitin-Activating Enzymes Receptors, Estrogen Receptors, Vascular Endothelial Growth Factor Estrogen Receptor Modulators Sulfones Sirolimus Leucovorin Receptors, Growth Factor Nitroimidazoles Piperidines Cytotoxins Vinblastine Intercellular Signaling Peptides and Proteins Cytochrome P-450 CYP3A Receptors, Progesterone Benzenesulfonates Etoposide Niacinamide Quinolines Collagen Type III Acridines Phenylurea Compounds Pyrimidines Morpholines P-Glycoprotein RNA, Messenger Pyrroles Chromones Fluorine Radioisotopes

Analytical, Diagnostic and Therapeutic Techniques and Equipment64

Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Xenograft Model Antitumor Assays DNA Mutational Analysis Survival Analysis Drug Screening Assays, Antitumor Disease-Free Survival Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Administration, Oral Maximum Tolerated Dose In Situ Hybridization, Fluorescence Inhibitory Concentration 50 Neoplasm Staging Kaplan-Meier Estimate Survival Rate Drug Administration Schedule Salvage Therapy Blotting, Western Drug Approval Individualized Medicine Clinical Trials as Topic Prognosis Clinical Trials, Phase I as Topic Retreatment Chemoradiotherapy Reverse Transcriptase Polymerase Chain Reaction Retrospective Studies Tumor Burden Area Under Curve Scintillation Counting Predictive Value of Tests Combined Modality Therapy Immunohistochemistry Treatment Failure Induction Chemotherapy Tomography, X-Ray Computed Transplantation, Heterologous Gene Expression Profiling Neoplasm Transplantation Karnofsky Performance Status Sensitivity and Specificity Immunoblotting Multivariate Analysis Disease Models, Animal Flow Cytometry Patient Selection Randomized Controlled Trials as Topic Molecular Targeted Therapy Infusions, Intravenous Prospective Studies Comet Assay Endpoint Determination Probability Gene Knockdown Techniques Immunoenzyme Techniques Positron-Emission Tomography Drug Evaluation, Preclinical Proportional Hazards Models Oligonucleotide Array Sequence Analysis Chemotherapy, Adjuvant Drug Design Pilot Projects Follow-Up Studies

Psychiatry and Psychology1

Phenomena and Processes38

Genes, erbB-1 Drug Resistance, Neoplasm Mutation Phosphorylation Cell Proliferation Signal Transduction Dose-Response Relationship, Drug Drug Synergism Apoptosis Maximum Tolerated Dose Gene Expression Regulation, Neoplastic Inhibitory Concentration 50 Gene Dosage Genes, erbB-2 Gene Amplification Exons Genes, ras Cell Cycle Cell Survival Area Under Curve Cell Growth Processes Time Factors Mutation, Missense Drug Interactions Epithelial-Mesenchymal Transition Down-Regulation G1 Phase Point Mutation Drug Resistance, Multiple Sequence Deletion Sensitivity and Specificity Tissue Distribution Drug Antagonism Base Sequence Radiation Tolerance Probability Enzyme Activation MAP Kinase Signaling System

Disciplines and Occupations4

Individualized Medicine Immunohistochemistry Drug Design Pharmacogenetics

Anthropology, Education, Sociology and Social Phenomena3

Drug Approval United States Food and Drug Administration Quality of Life

Humanities1

Quality of Life

Information Science3

Survival Rate Base Sequence Molecular Sequence Data

Named Groups1

Asian Continental Ancestry Group

Health Care25

Treatment Outcome Survival Analysis Disease-Free Survival Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Kaplan-Meier Estimate Survival Rate Clinical Trials as Topic Clinical Trials, Phase I as Topic Retrospective Studies Area Under Curve Predictive Value of Tests United States Food and Drug Administration Medical Assistance Treatment Failure Karnofsky Performance Status Sensitivity and Specificity Multivariate Analysis Patient Selection Randomized Controlled Trials as Topic Prospective Studies Probability Proportional Hazards Models Pilot Projects Follow-Up Studies

Geographicals2

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Named Groups Health Care Geographicals

Quinazolines Receptor, Epidermal Growth Factor Antineoplastic Agents Lung Neoplasms Carcinoma, Non-Small-Cell Lung Protein Kinase Inhibitors Genes, erbB-1 Drug Resistance, Neoplasm Cell Line, Tumor Adenocarcinoma Mutation Receptor, erbB-3 Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Proto-Oncogene Proteins c-akt Xenograft Model Antitumor Assays Phosphorylation DNA Mutational Analysis Exanthema Cell Proliferation Meningeal Carcinomatosis Survival Analysis Receptor, erbB-2 Head and Neck Neoplasms Signal Transduction Mice, Nude Epidermal Growth Factor Carcinoma, Squamous Cell Drug Screening Assays, Antitumor Dose-Response Relationship, Drug Drug Synergism Lung Diseases, Interstitial Disease Progression Disease-Free Survival Clinical Trials, Phase II as Topic Antibodies, Monoclonal, Humanized Taxoids Apoptosis Clinical Trials, Phase III as Topic Administration, Oral Maximum Tolerated Dose Gene Expression Regulation, Neoplastic In Situ Hybridization, Fluorescence Adenocarcinoma, Bronchiolo-Alveolar Topotecan Quinazolinones Inhibitory Concentration 50 Proto-Oncogene Proteins Protein-Tyrosine Kinases Neoplasm Staging Gene Dosage Kaplan-Meier Estimate Proto-Oncogene Proteins c-met Survival Rate Paclitaxel Cisplatin Brain Neoplasms ras Proteins Drug Administration Schedule Tumor Markers, Biological Genes, erbB-2 Salvage Therapy Gene Amplification Camptothecin Blotting, Western ATP-Binding Cassette Transporters Breast Neoplasms Drug Approval Extracellular Signal-Regulated MAP Kinases Individualized Medicine Exons Neoplasm Recurrence, Local Clinical Trials as Topic Carboplatin Tumor Cells, Cultured Antibodies, Monoclonal Neoplasms Prognosis Clinical Trials, Phase I as Topic Retreatment Chemoradiotherapy Brain Stem Neoplasms Mitogen-Activated Protein Kinase 3 Biomarkers, Pharmacological Carcinoma, Adenosquamous Transforming Growth Factor alpha Genes, ras Diarrhea Reverse Transcriptase Polymerase Chain Reaction Cell Cycle Deoxycytidine Cell Survival Retrospective Studies Tumor Burden Area Under Curve Cell Growth Processes PTEN Phosphohydrolase Time Factors Protein-Serine-Threonine Kinases Receptor, IGF Type 1

No FAQ available that match "gefitinib"